In the subsequent CAVALLI study, addition of the highly selective BCL2 inhibitor venetoclax to R-CHOP was associated with an improvement in PFS and OS in patients with previously untreated BCL2 positive (by immunohistochemistry [IHC]) DLBCL, when compared with a matched historical control group treated with R-CHOP alone in GOYA [19, 20]. Here, BCL2 is linked to diffuse large B-cell lymphoma.